"The new type of chemotherapeutic drug PtNC@BSA-iRGD exhibits excellent antitumor activity in vitro/vivo, in comparison to clinical commercial first-line carboplatin. "
"More impressively, compared to first-line platinum chemotherapy drugs, PtNC@BSA-iRGD has superior biocompatibility while possessing higher tumor inhibitory activity in vivo during medication treatment. "